Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
Colorectal Cancer
Colorectal Cancer Stage IV

Interventions

DRUG: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab

Sponsor

Northwestern University

Collaborators

[object Object]